SEC Form 4 · accession 0001181190-26-000005
Cytek Biosciences, Inc. · CTKB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn P Muir
Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 7:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001831915
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jun 10, 2026 | A | 55,555 | A | — | — | Common Stock | 55,555 | 55,555 | D |
| Director Stock Option (right to buy)F3 | $4.05 | Jun 10, 2026 | A | 29,835 | A | — | Jun 10, 2036 | Common Stock | 29,835 | 29,835 | D |
Explanation of responses
- F1Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F22/36 of the total shares subject to the RSU Award shall vest on August 18, 2026; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2027 and each August 18 thereafter, until fully vested.
- F31/36 of the total shares subject to the option shall vest monthly over 3 years following the grant date of June 10, 2026.